drugset / Trial / NCT04630353
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
Timeline
- Start
- 2021-07-21
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB-201 | Vaccine | — | Intravenous |